

Atty Docket No. 10692V-000210US

PTO FAX NO.: 703.746.3143

ATTENTION: Examiner Shengjun Wang  
Group Art Unit 1617

**OFFICIAL COMMUNICATION  
FOR THE PERSONAL ATTENTION OF  
EXAMINER Shengjun Wang**

**CERTIFICATION OF FACSIMILE TRANSMISSION**


I hereby certify that the following documents, in re Application of Adams *et al.*, Application No. 09/177,711, filed October 23, 1998, for COMBINATION THERAPY FOR TREATMENT OF ERECTILE DYSFUNCTION is being facsimile transmitted to the Patent and Trademark Office on the date shown below.

Documents Attached

1. Amendment filed on January 9, 2002

Number of pages being transmitted, including this page: 11

Dated: March 20, 2002

  
Debra Ann DeBello

**PLEASE CONFIRM RECEIPT OF THIS PAPER BY  
RETURN FACSIMILE AT (415) 576-0300**

TOWNSEND and TOWNSEND and CREW LLP  
Two Embarcadero Center, 8th Floor  
San Francisco, CA 94111-3834  
Telephone: (415) 576-0200  
Fax: (415) 576-0300

SF 150004 v1

#247  
002  
JMP  
3/21/02

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

**PATENT**  
Attorney Docket No.: 10692V-000210US

Assistant Commissioner for Patents  
Washington, D.C. 20231

On January 9, 2002

TOWNSEND and TOWNSEND and CREW LLP

By: Debra A. DeBello  
Debra Ann DeBello

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re application of:

Adams *et al.*

Application No.: 09/177,711

Filed: October 23, 1998

For: COMBINATION THERAPY FOR  
TREATMENT OF ERECTILE  
DYSFUNCTION

Art Unit: 1617

Examiner: Wang, S.

**AMENDMENT**

Assistant Commissioner for Patents  
Washington, D.C. 20231

Sir:

In response to the Office Action mailed July 11, 2001, please amend the above-identified application as follows. A petition for a three-month extension of time is being submitted concurrently herewith.

**IN THE CLAIMS:**

Please amend claims 60 and 70 as follows:

1 60. (Amended) A method of decreasing pain associated with use of  
2 prostaglandins for treatment of erectile tissue dysfunction comprising administering to a  
3 subject in need of prostaglandin at least one NO producing agent at a low dose which